Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
PepGen Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
PEPG
Nasdaq
2834
pepgen.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for PepGen Inc.
PepGen price target lowered to $16 from $26 at H.C. Wainwright
- Jan 31st, 2025 12:21 pm
PepGen Announces CONNECT Program Updates
- Jan 29th, 2025 9:05 pm
All You Need to Know About PepGen (PEPG) Rating Upgrade to Buy
- Jan 8th, 2025 5:00 pm
PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy
- Dec 16th, 2024 1:00 pm
PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development
- Nov 21st, 2024 9:05 pm
PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
- Nov 7th, 2024 1:00 pm
We're Keeping An Eye On PepGen's (NASDAQ:PEPG) Cash Burn Rate
- Nov 6th, 2024 1:14 pm
PepGen to Participate in Upcoming Investor Conferences
- Nov 4th, 2024 1:00 pm
PepGen Announces Presentations at the 29th Annual Congress of the World Muscle Society
- Oct 8th, 2024 11:00 am
PepGen Announces Christopher Ashton, PhD, to Retire from its Board of Directors
- Sep 19th, 2024 8:30 pm
PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Vice President, Research & Development
- Aug 20th, 2024 8:05 pm
PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development
- Aug 20th, 2024 12:00 pm
Is PepGen Inc. (NASDAQ:PEPG) Trading At A 34% Discount?
- Aug 17th, 2024 12:37 pm
PepGen Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
- Aug 8th, 2024 12:00 pm
Down -39.63% in 4 Weeks, Here's Why You Should You Buy the Dip in PepGen (PEPG)
- Aug 2nd, 2024 1:35 pm
PepGen reports positive data from Phase II Duchenne muscular dystrophy trial
- Jul 31st, 2024 8:52 am
PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy
- Jul 30th, 2024 8:02 pm
Recent Price Trend in PepGen (PEPG) is Your Friend, Here's Why
- Jul 17th, 2024 12:50 pm
PepGen Appoints Afsaneh Mohebbi, Ph.D., as SVP, Portfolio and Program Management and Dave Borah, CFA, as SVP, Investor Relations and Corporate Communications
- Jul 2nd, 2024 12:00 pm
PepGen Announces Executive Team Promotions
- Jun 11th, 2024 11:00 am
Scroll